Top Page
ARS Pharmaceuticals
(NASDAQ:SPRY)
ARS Pharmaceuticals (SPRY) vs. SPDR S&P 500 ETF (SPY)
ARS Pharmaceuticals Business Overview & Revenue Model
ARS Pharmaceuticals Earnings Call Summary
ARS Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 142.77M | 89.15M | 30.00K | 1.32M | 5.51M | 17.84M |
| Gross Profit | 121.66M | 68.59M | 30.00K | 1.32M | 5.29M | 3.77M |
| EBITDA | -83.07M | -3.00M | -67.45M | -35.20M | -19.24M | -463.00K |
| Net Income | -80.04M | 8.00M | -54.37M | -34.68M | -20.24M | -1.06M |
Balance Sheet | ||||||
| Total Assets | 372.80M | 351.15M | 233.19M | 281.44M | 61.45M | 26.41M |
| Cash, Cash Equivalents and Short-Term Investments | 288.21M | 314.02M | 228.36M | 274.38M | 60.06M | 24.52M |
| Total Debt | 1.53M | 42.00K | 274.00K | 481.00K | 9.03M | 10.02M |
| Total Liabilities | 225.15M | 94.36M | 2.43M | 8.55M | 92.72M | 40.46M |
| Stockholders Equity | 147.66M | 256.80M | 230.76M | 272.89M | -31.27M | -14.05M |
Cash Flow | ||||||
| Free Cash Flow | -86.02M | 12.98M | -59.44M | -40.28M | -17.62M | 8.15M |
| Operating Cash Flow | -85.38M | 13.55M | -59.27M | -40.08M | -17.56M | 9.07M |
| Investing Cash Flow | -69.11M | -106.10M | -87.18M | -199.00K | -55.00K | -917.00K |
| Financing Cash Flow | 174.38M | 72.40M | 6.90M | 190.73M | 53.16M | 5.10M |
ARS Pharmaceuticals Technical Analysis
ARS Pharmaceuticals Risk Analysis
ARS Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $1.16B | 1,223.61 | 0.44% | ― | 26.54% | ― | |
59 Neutral | $1.57B | ― | -36.13% | ― | ― | ― | |
55 Neutral | $1.32B | -25.81 | -36.87% | ― | ― | 15.84% | |
52 Neutral | $723.57M | ― | -45.92% | ― | 5459.66% | -59.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $1.19B | ― | -39.73% | ― | ― | 4.29% |
ARS Pharmaceuticals Corporate Events
ARS Pharmaceuticals, Inc., a biopharmaceutical company, focuses on empowering patients and caregivers to manage allergic reactions, particularly through its innovative needle-free epinephrine nasal spray, neffy.
During Ars Pharmaceuticals, Inc.’s latest earnings call, the sentiment was largely positive, underscored by significant revenue growth and strategic initiatives. The company celebrated the success of its ‘Get Nephi On Us’ program and global expansion plans. However, challenges such as temporary pauses in market share growth, data inaccuracies, and an anticipated decline in Q4 sales were acknowledged.
On November 10, 2025, ARS Pharmaceuticals reported its third-quarter financial results, highlighting $32.5 million in revenue, primarily from U.S. sales of neffy®. The company is actively expanding its market presence with direct-to-consumer campaigns and strategic initiatives to increase prescriber confidence and patient access. Despite a net loss of $51.2 million, ARS Pharmaceuticals maintains a strong cash position to support its operations and growth. The company is also progressing with the global expansion of neffy, having received approval in Japan and launched EURneffy® in the U.K., with further regulatory approvals anticipated in Canada and China. These efforts are expected to enhance ARS Pharmaceuticals’ industry positioning and stakeholder engagement.
The most recent analyst rating on (SPRY) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on ARS Pharmaceuticals stock, see the SPRY Stock Forecast page.
Study Overview: Ars Pharmaceuticals, Inc. is conducting a Phase IV study titled ‘A Phase IV Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy.’ The study aims to assess the safety and efficacy of Neffy, an epinephrine nasal spray, and intramuscular Adrenalin in managing allergic reactions following oral food challenges or allergen immunotherapy. This research holds significant importance in potentially offering a more convenient treatment option for allergic reactions.
Study Overview: Ars Pharmaceuticals, Inc. is conducting a study titled ‘An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria.’ This study aims to evaluate the effectiveness of ARS-2 in treating patients with chronic spontaneous urticaria (CSU), a condition characterized by recurrent hives. The study’s significance lies in its potential to offer a new treatment option for individuals suffering from moderate to severe CSU flare-ups.
On September 29, 2025, ARS Pharmaceuticals, Inc. entered into a credit agreement with RA Capital Agency Services, LLC and other lenders for up to $250 million in term loans. The funds will be used for product development and general corporate purposes, with the first tranche of $100 million already advanced. This agreement is expected to support ARS Pharmaceuticals’ growth and enhance its market position, with implications for stakeholders including RA Capital, which holds a significant stake in the company.
The most recent analyst rating on (SPRY) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on ARS Pharmaceuticals stock, see the SPRY Stock Forecast page.
The recent earnings call from Ars Pharmaceuticals, Inc. painted a largely positive picture, with significant growth in revenue and prescription volume for their flagship product, Neffy. The company also highlighted its expanding global presence and commercial coverage. While there were concerns regarding high SG&A expenses and challenges with prior authorization requirements, the overall sentiment was optimistic, driven by strong revenue growth and strategic global expansion.
On August 13, 2025, ARS Pharmaceuticals received a Paragraph IV certification notice from Lupin Inc., indicating that Lupin has filed an Abbreviated New Drug Application with the FDA to produce a generic version of ARS’s neffy© nasal spray before the expiration of several patents. ARS plans to defend its patents vigorously by filing a patent infringement lawsuit against Lupin, which could delay FDA approval of Lupin’s generic product by 30 months if filed within 45 days. The outcome of this legal action remains uncertain, but it could significantly impact ARS’s market position and intellectual property rights.
The most recent analyst rating on (SPRY) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on ARS Pharmaceuticals stock, see the SPRY Stock Forecast page.